Clinical Trial News and Research

RSS

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.

4 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

UBC receives $7M grant from Bill & Melinda Gates Foundation for PRE-EMPT Project

The University of British Columbia has received a $7 million grant from the Bill & Melinda Gates Foundation. UBC researchers working at the Child & Family Research Institute will test new strategies for the monitoring, prevention, and treatment of pre-eclampsia.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting

SuperGen, Inc. today announced that a summary of preclinical efficacy, safety, and pharmacokinetics data of SGI-110 will be presented at the American Society of Hematology in Orlando on Saturday, December 4, 2010 at 5:30 pm ET.

3 Dec 2010

Loyola nurses honored

Loyola University Health System revenue specialist Judy Williams, RN, CEN, TNS, recently took on a nontraditional nursing role, which resulted in a significant cost savings for the organization. Williams oversees fiscal responsibility for the Emergency Department. In this position, she has identified opportunities to overcome billing obstacles through intradepartmental collaboration and nurse education on proper documentation for reimbursement.

3 Dec 2010

Prostate cancer imaging shows real-time tumor metabolism

A UCSF research collaboration with GE Healthcare has produced the first results in humans of a new technology that promises to rapidly assess the presence and aggressiveness of prostate tumors in real time, by imaging the tumor's metabolism.

3 Dec 2010

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Cell Therapeutics, Inc. today announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug Application to treat relapsed/refractory aggressive non-Hodgkin's lymphoma.

3 Dec 2010

Doctors still prescribe higher-dose menopausal hormone therapy pills

Doctors across the country are still prescribing higher-dose menopausal hormone therapy pills, despite clinical evidence that low doses and skin patches work just as well and carry fewer health risks. That's what researchers at the Stanford University School of Medicine found in a study that will be published online Dec. 2 in Menopause: The Journal of the North American Menopause Society.

3 Dec 2010

MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers

BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers.

3 Dec 2010

FDA accepts to file PMA application for LightTouch Cervical Scanner

Guided Therapeutics, Inc. announced that it was notified by the U.S. Food and Drug Administration (FDA) that the company's premarket approval application (PMA) for the LightTouch Cervical Scanner, for patients at risk for cervical cancer, is suitable for filing.

3 Dec 2010

FDA accepts IND application to initiate human clinical trial to evaluate BNC

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company's second product, bisnorcymserine (BNC).

3 Dec 2010

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

Sirnaomics, Inc. announced today that the company has cemented a partnership with a Chinese pharmaceutical company for development of its small interfering RNA (siRNA) therapeutic (STP705) for scarless wound healing.

3 Dec 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), in combination with paclitaxel (with or without bevacizumab) in patients with locally recurrent or metastatic breast cancer.

3 Dec 2010

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).

2 Dec 2010

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced results from its first Phase 3 trial post hoc analysis in which the higher body mass index (BMI) of the U.S. population relative to the Indian population was a likely key contributor to the more positive effects of D-tagatose in the lowering of HbA1c levels in the U.S. population. Initial results were announced on October 7.

2 Dec 2010

ASH honors Sen. Sherrod Brown and Erik Fatemi

The American Society of Hematology (ASH) will honor Senator Sherrod Brown (D-OH) with the 2010 ASH Award for Public Service and Erik Fatemi, Majority Clerk for the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS), with the Award for Outstanding Service in recognition of their dedication to championing health care and research issues. These awards will be officially announced at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando, FL.

2 Dec 2010

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

2 Dec 2010

Soy bean derived compound could treat Sanfilippo genetic disease in children

Scientists from The University of Manchester say a naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children.

2 Dec 2010

Biodiversity degradation may have perverse consequences for emerging pathogens

Habitat destruction and species extinction may lead to an increase in diseases that infect humans and other species, according to a paper in the journal Nature co-authored by a University of Florida ecologist.

2 Dec 2010

Clinical Trial News and Research

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

URMC's Cone Beam CT scanner studies presented at RSNA 2010

UBC receives $7M grant from Bill & Melinda Gates Foundation for PRE-EMPT Project

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

SuperGen to present SGI-110 data for MDS, AML at ASH annual meeting

Loyola nurses honored

Prostate cancer imaging shows real-time tumor metabolism

Cell Therapeutics submits pixantrone NDA application to treat non-Hodgkin's lymphoma

Doctors still prescribe higher-dose menopausal hormone therapy pills

MHRA issues notice of acceptance for BioMarin's BMN 673 for genetically-defined cancers

FDA accepts to file PMA application for LightTouch Cervical Scanner

FDA accepts IND application to initiate human clinical trial to evaluate BNC

Sirnaomics cemented partnership with Chinese pharmaceutical to develop siRNA therapeutics

Geron commences enrollment in imetelstat Phase 2 clinical trial for metastatic breast cancer

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

Spherix announces results of D-tagatose Phase 3 trial for Type 2 diabetes

ASH honors Sen. Sherrod Brown and Erik Fatemi

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

Soy bean derived compound could treat Sanfilippo genetic disease in children

Biodiversity degradation may have perverse consequences for emerging pathogens

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer